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a-Thrombin  derivatives  obtained  either  by site-spe- 
cific  modification at lysyl  residues  (phosphopyridoxy- 
lated) or by limited  trypsinolysis (yT-thrombin) were 
compared to correlate structural modifications with 
the functional  reactivity  toward  fibrin(ogen)  and hep- 
arin.  a-Thrombin phosphopyridoxylated  in the absence 
of heparin (unprotected) showed  approximately 2 mol 
of label incorporated/mol of thrombin,  but  only 1 mol 
of label  incorporated/mol of proteinase  when modified 
in  the presence of added  heparin (protected). In con- 
trast to  native  a-thrombin,  both  phosphopyridoxylated 
a-thrombin  derivatives  failed  to  interact  with a fibrin 
monomer-agarose column and  had reduced  fibrinogen 
clotting  activity,  which is very  similar to yT-thrombin. 
Heparin  accelerated  the rate of antithrombin I11 inhi- 
bition of a-thrombin, heparin-protected modified-a- 
thrombin,  and yT-thrombin in a manner consistent with 
a template mechanism but  was  without  effect  on  un- 
protected modified a-thrombin. In a heparin-catalyzed 
antithrombin I11 inhibition assay of a-thrombin, we 
found that D-Phe-Pro-Arg  chloromethyl  ketone-active 
site-inactivated yT-thrombin competed for  heparin 
binding. It has been shown that limited proteolysis/ 
autolysis of the B-chain of a-thrombin in the area 
around  Arg-B73  (in  and  yT/y-thrombin),  but  not 
that  around  Lys-B154  (in yT/y-thrombin),  diminishes 
specific interactions  with  fibrinogen (Hofsteenge, J., 
Braun, P. J., and Stone, S. R. (1988) Biochemistry 27, 
2144-2151). In unprotected modified a-thrombin,  ly- 
syl  residues  B21,  B65,  B174,  and  B252  were phospho- 
pyridoxylated. In heparin-protected modified a- 
thrombin,  only  lysyl  residues  B2 1 and  B65  were phos- 
phopyridoxylated.  These  observations  suggest hat ly- 
syl  residues  21/65 of the B-chain of a-thrombin are 
involved in fibrin(ogen) interactions, and  lysyl resi- 
dues 1741252 of the B-chain are important  in  heparin 
interactions. 
a-Thrombin  (EC 3.4.21.5) is a  trypsin-like serine proteinase 
that plays a key  role both in blood coagulation and in other 
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physiological processes that involve catalytic functions  and 
nonenzymatic intermolecular interactions (1-3). Thrombin 
cleaves or interacts with many different blood components 
including fibrinogen, fibrin, platelets, coagulation factors V, 
VIII, and  XIII, thrombomodulin, and  protein C. One mecha- 
nism for regulating thrombin activity is inhibition by plasma 
proteinase inhibitors, including antithrombin 111, heparin CO- 
factor 11, al-proteinase inhibitor, and az-macroglobulin (4). 
Antithrombin I11 and heparin cofactor I1 are distinguished 
from the other proteinase inhibitors by their ability to show 
greatly accelerated thrombin inhibition in the presence of 
heparin  and  other glycosaminoglycans (see Refs. 5 and 6 and 
references cited therein). The heparin-catalyzed thrombin 
inhibition reaction with antithrombin I11 (and  heparin cofac- 
tor 11) requires simultaneous binding of proteinase and  pro- 
teinase inhibitor to heparin (7-10). 
The physiological substrate specificity of a-thrombin is 
mediated through both the active site region and  a  separate 
binding site(s) associated with the active site (11). a-Throm- 
bin autolysis or limited proteolysis with trypsin yields 8- and 
y-thrombin derivatives (12). @T/yT-Thrombin and Ply-  
thrombin (obtained by trypsinolysis ( ~ T / Y T )  or autolysis (p/ 
y), respectively) have virtually no fibrinogen clotting ability 
but  are active toward synthetic  substrates.  Structural analysis 
of human yT/y-thrombin reveals that 5 basic amino acid 
residues in the B-chain, Arg-B62, Arg-B70, Arg-B73, Arg- 
B123, and Lys-B154, are highly susceptible to proteolysis (12- 
16). Recent work with &-thrombin (cleavage only at Arg- 
B73) suggests that  the P-cleavage site in a-thrombin is directly 
involved in  interactions with fibrin(ogen), protein C, throm- 
bomodulin, and hirudin (17-19). 
a-Thrombin  has  a  net positive surface charge of approxi- 
mately 7 at physiological pH (20). As a polycation, a-thrombin 
binds not only to heparin (a highly  negatively charged glycos- 
aminoglycan) but also other polyanionic substances (21-24). 
The importance of positively charged lysyl residues of 
(pro)thrombin in polyanion binding and macromolecular pro- 
tein  interactions (such as with fibrinogen, antithrombin 111, 
and factor V) has been examined by specific chemical modi- 
fication (25-29). Griffith (26) showed that there  are relatively 
few lysyl residues in a-thrombin that  are essential for fibrin- 
ogen clotting activity and heparin binding. 
This report further examines the importance of a-thrombin 
lysyl residues in binding to heparin  and fibrin(ogen). For this 
study, we compared the structural and functional properties 
of a-thrombin chemically modified with pyridoxal 5’-phos- 
phate  (in  the absence and presence of added heparin) to those 
of a-thrombin  and ydhrombin. We have also identified the 
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position of the modified lysyl residues in the amino acid 
sequence of a-thrombin. 
EXPERIMENTAL PROCEDURES AND RESULTS”~ 
DISCUSSION 
The purpose of this investigation was to  further character- 
ize the reaction properties of phosphopyridoxylated a-throm- 
bin species compared to  a-thrombin  and yT-thrombin and  to 
identify some of the lysyl residues that  are involved in  heparin 
and fibrin(ogen) interactions. The present  study and previous 
work (26) have used pyridoxal 5”phosphate modification of 
lysyl residues of thrombin to produce a  proteinase  with greatly 
reduced fibrin(ogen) clotting and binding activities, but with 
a competent active site (catalytic triad). Analysis of a-throm- 
bin treated with pyridoxal 5’-phosphate reveals that 4 out of 
a total of  22 lysyl residues are highly susceptible to modifi- 
cation. Selective modification of lysyl residues 21, 65, 174, 
and 252 in the B-chain of a-thrombin account for -80% of 
the  total phosphopyridoxyl incorporati~n.~.~ We  feel that  the 
contribution of other, minimally modified peptides to any 
decrease in  a-thrombin activity would  be minor. 
Comparison of the thrombin derivatives to GdnHCl  dena- 
turation showed that ydhrombin is more labile than a- 
thrombin and phosphopyridoxylated a-thrombins.  These ob- 
servations agree with  urea denaturation studies of proteolyzed 
a-thrombin derivatives (2, 19). While the €-amino group- 
labeled a-thrombin molecules produced by phosphopyridox- 
ylation resemble native a-thrombin, limited proteolysis in  the 
B-chain of a-thrombin produces a protein structure more 
susceptible to  denaturation. 
’ Portions of this paper (including “Experimental Procedures,” 
“Results,” Tables I and 11, and Figs.  1-5) are presented in  miniprint 
at  the end of this paper. Miniprint is easily read with the aid of a 
standard magnifying  glass. Full size photocopies are included in the 
microfilm edition of the Journal that is available from Waverly Press. 
The abbreviations used are: BSA,  bovine serum albumin; TosPhe- 
CH2C1, tosylphenylalanine chloromethyl ketone; TosGlyPro- 
ArgNA, No-p-tosyl-Gly-Pro-Arg-p-nitroanilide; HEPES, 4-(2-hy- 
droxyethy1)-1-piperazineethanesulfonic acid dansyl-Glu-Gly-Arg- 
CHZCl, dansyl-Glu-Gly-Arg chloromethyl ketone; D-Phe-Pro-Arg- 
CH,Cl, D-Phe-Pro-Arg chloromethyl ketone; DAPA, dansylarginine 
N-(3-ethyl-1,5-pentanediyl)amide; SDS-PAGE, sodium dodecyl sul- 
fate-polyacrylamide gel electrophoresis; GdnHC1, guanidine hydro- 
chloride; ELISA, enzyme-linked immunosorbent assay; HPLC, high 
performance liquid chromatograph(y). 
Lysyl residues 21, 65, 174, and 252 in the B-chain of a-thrombin 
correspond to lysyl residues 341, 385, 494, and 572 in the zymogen, 
prothrombin, respectively (45). 
‘ Our data demonstrate that while 2 residues are modified, the total 
incorporation of pyridoxyl phosphate is 1 mol/mol of a-thrombin  (in 
the presence of heparin). Our interpretation is that  the residues found 
to be essential for fibrin(ogen) interactions, Lys-B21 and Lys-B65, 
have an initial equal opportunity of being phosphopyridoxylated, but 
following modification of either amino acid residue steric hindrance 
(or  a localized conformational change) blocks or limits further mod- 
ification (reactivity) of the other lysyl residue. Therefore, our obser- 
vations suggest that modification of either reactive lysyl residue 
results in the loss of a-thrombin fibrin(ogen) activity. A similar 
explanation can be argued for the other 2 residues modified in a- 
thrombin, Lys-Bl74 and Lys-B252, which were determined to be 
important for heparin interactions. The individual contribution of a- 
thrombin B-chain lysyl residues 21 and 65 during fibrin(ogen) inter- 
action and lysyl residues 174 and 252 during heparin binding is 
currently being evaluated using antipeptide antibodies prepared to 
synthetic peptides containing each respective lysyl residue. Noe et ul. 
(46) recently demonstrated that an  antipeptide polyclonal antibody 
prepared against residues 62-73 of the a-thrombin B-chain competi- 
tively inhibited not only fibrinogen clotting activity but also other 
enzymic functions without affecting tripeptidyl p-nitroanilide sub- 
strate hydrolysis by the proteinase. 
The conformations of the phosphopyridoxylated a-throm- 
bins and yT-thrombin were compared to a-thrombin using 
monoclonal antibodies  prepared  against a-thrombin (41). In- 
terestingly, a-thrombin and heparin-protected modified a- 
thrombin reacted essentially the same with the monoclonal 
antibodies directed to fibrin(ogen)-specific epitopes on a- 
thrombin (ESTB, -6, and -7). Unprotected modified a-throm- 
bin and yT-thrombin were similar to each other  and showed 
reduced ability to  interact with EST2, -6, and -7. This differ- 
ential reactivity suggests that a specific protein  conformation 
is conserved in heparin-protected modified a-thrombin. In 
contrast, the lowered reactivity of unprotected modified a- 
thrombin and ydhrombin suggests an altered  protein con- 
formation (either  by chemical modification of lysyl residues 
B-21,  B-65, B-174, and B-252 or by limited proteolysis near 
Arg-B73 and/or Lys-B154) that is poorly  recognized  by these 
monoclonal antibodies (ESTZ, -6, and -7). 
Lysyl residues 21 and 65 of the B-chain of a-thrombin  are 
modified both  in  the absence and presence of added heparin. 
Peptide bond cleavage in y/yT-thrornbin occurs within the 
regions containing Arg-B62 to Arg-B73 and Arg-B123 to Lys- 
B154 (12-16). Loss of clotting activity is correlated solely 
with proteolysis in  the region centered  around Arg-73 in  the 
B-chain of a-thrombin (13, 18, 19). Whether or not the 
activity loss demonstrated in  a-thrombin following limited 
proteolysis/chemical modification is the result of a confor- 
mation change, these observations suggest that the areas 
around Lys-BZI, Lys-B65, and Lys-B73 are important for 
fibrin(ogen) interactions? 
a-Thrombin fibrinogen clotting and fibrin monomer bind- 
ing activities are inhibited by negatively charged nucleotides 
and  other anionic compounds (22,  23). It appears that fibrin 
binding to  a-thrombin involves an “anionic binding site” (or 
“recognition site”)  in  the proteinase (14, 15, 24). Unlike a- 
thrombin, yT-thrombin does not interact with immobilized 
fibrin monomer (15). In the present  study using ??.-thrombin 
and lysine-modified a-thrombin species, we investigated 
whether both fibrin and heparin  binding occur at  the same 
site in  a-thrombin. We found that  the interaction with im- 
mobilized fibrin monomer was greatly reduced for both hep- 
arin-  and non-heparin-binding species of phosphopyridoxy- 
lated a-thrombin (see below for the heparin binding properties 
of yT-thrombin). For  these reasons, we conclude either  that 
the heparin and fibrin binding  sites  in a-thrombin  are differ- 
ent or that if they are the same  site, then  the requirements 
for fibrin binding are more extensive than for heparin binding. 
The effect of either phosphopyridoxylation or limited pro- 
teolysis of a-thrombin on the  rate of inhibition by antithrom- 
bin 111 is small. The results  with yT-thrombin are  consistent 
with recently published observations of proteolyzed thrombin 
derivatives and indicate that  the region of a-thrombin cen- 
tered  around Arg-B73 and Lys-B154 is not significantly in- 
volved in  interaction with antithrombin I11 (19,471. Likewise, 
the lysine residues modified by phosphopyridoxylation are 
not required for the interaction  with antithrombin I11 (in the 
absence of heparin). 
Elution of the thrombin derivatives from immobilized hep- 
arin revealed that only unprotected modified a-thrombin 
eluted abnormally, while heparin-protected modified a- and 
yT-thrombin  eluted essentially at  the same ionic strength  as 
native a-thrombin. A comparison of &-thrombin,  unprotected 
and heparin-protected modified a-thrombins,  and yT-throm- 
bin inhibition by antithrombin 111 over a broad range of 
heparin  concentrations (44) indicates that  the heparin  bind- 
ing site in heparin-protected modified a-thrombin and YT- 
thrombin is totally functional. We also showed that YT- 
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FIG. 6. Schematic model of the active site region of a- 
thrombin illustrating the relationships between functional 
portions of the proteinase (B-chain) involved in interactions 
with fibrin(ogen) and heparin. The catalytic active site triad 
residues (histidine (H-43),  aspartic acid (D-99), and serine  (S-205)) 
are shown within the triangle. 
thrombin (with its active site blocked by D-Phe-Pro-Arg- 
CH,Cl) can compete for heparin binding to  a-thrombin during 
a heparin-catalyzed antithrombin I11 inhibition reaction. 
These  results suggest that neither proteolysis of a-thrombin 
near the area of Arg-B73 and Lys-B154 (7,-thrombin) nor 
site-selective chemical modification at Lys-B21 and Lys-B65 
(heparin-protected modified a-thrombin) compromises hepa- 
rin binding. Our results also indicate that modification of 
Lys-B174 and Lys-B252 of a-thrombin greatly reduces pro- 
teinase-heparin binding; thus, these residues are required for 
the interaction with heparin. 
These observations and previous reports (see references 
cited below) can be used to construct  a model relating the 
fibrin(ogen) and heparin binding sites  in  a-thrombin. This is 
schematically shown in Fig. 6. As illustrated, the overall 
fibrin(ogen) binding area is composed of the “recognition site” 
and  the “apolar site” (11, 14, 15). The rationale for showing 
the recognition site for fibrinogen and fibrin as overlapping 
is based on limited proteolysis studies of a-thrombin in which 
both fibrinogen and fibrin interactions are greatly reduced 
without affecting binding to the apolar site (that is, YT- 
thrombin does not interact with fibrin(ogen) but can still 
effectively bind to D-Phe-Pro-Arg-CH&l). Chemical modifi- 
cation of Lys-B21 and Lys-B65 also uncouples the fi- 
brin(ogen)  interactions of the recognition site. The model also 
depicts the heparin binding site as  a  distinct region but with 
a conformation-dependent linkage to the recognition site. 
Proteolyzed a-thrombin derivatives (such as 7,-thrombin) 
bind heparin essentially like the native molecule. Heparin- 
protected modified a-thrombin, which resembles native a -  
thrombin in its ability to react with both heparin and  the 
monoclonal antibodies, has lost its fibrin binding properties 
yet retains some fibrinogen clotting activity. Unprotected 
modified a-thrombin is greatly reduced in  all of these  prop- 
erties.  Chang  (48) has recently reported that Lys-B21, Lys- 
B65, and 4 other lysyl residues of a-thrombin are  protected 
from modification by 4-N,N-dimethylaminoazobenzene-4’- 
isothiocyano-2‘-sulfonic acid when the proteinase is com- 
plexed with hirudin. Additionally, he showed that Lys-B174 
becomes available for modification in a-thrombin following 
complex formation with hirudin (48). These observations are 
compatible not only with the essential role of Lys-B21 and 
Lys-B65 during fibrin(ogen) interactions but also with a  con- 
formational change centered  around Lys-B174 (including 
Lys-B252 as detected by phosphopyridoxylation) which is 
perturbed  during a-thrombin-hirudin interactions and is pro- 
tected  during phosphopyridoxylation by heparin. Evidence for 
significant a-thrombin conformational changes following 
binding to hirudin  has been described (49, 50). This model  is 
also consistent with a-thrombin-hirudin complexes having 
reduced affinity for immobilized heparin (51) as a conse- 
quence of an altered  protein  conformation  centered  around 
Lys-B174 (and presumably including Lys-B252). 
In conclusion, amino acid residues within a-thrombin  that 
are critical for substrate/cofactor binding have been charac- 
terizedusing chemical modification (25-29,48,52,53), limited 
proteolysis (1, 2, 12-19, 47, 51, 54), comparative structural 
modeling (55, 56), and naturally occurring genetic variants 
(57-60). Although not all the determinants for heparin or 
fibrin(ogen)  interactions with a-thrombin have been identi- 
fied, our  results  demonstrate the importance of B-chain lysyl 
residues 174 and 252 in  heparin binding and lysyl residues 21 
and 65 in fibrin(ogen) interactions. 
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Heparin  and Fibrin(ogen)  Interactions 
by 
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EWERIMENTAL PROCEDURES 
from the  Amencan Ked Cross ICarolinas Reglon, Charlotte,  NC) followmg prevmurly described 
Elat r r ia l r .  Prothrombm and ant8thrombm Dl were isolated from human plasma obtained 
procedures 130). Human a-thrombm war prepared lrom prothmmbm and purlfled as detatled 
prevlourly 1311. Human yy-thrombm was prepared  by  lmuted digestion wlth  trypsm as described 
116) Heprrm was generously  provided  by  Dr G van Dedem  (Dmrynth BV. O s ,  The 
Netherlands)  Heparin-agarore was prepared as dercrsbed prewausly (30). Pyndoxal 5. 
phosphate, B5A2, ToaPhe-CHzCI-treated  trypsm,  NaBHq.  DEAE-Sephacel, am-mouse IgG- 
slkalme phosphatase  conjugate  and  pnmophenyl  phosphate were obtamed from Lgma: bovine 
flbrmogen 175% clottable) was from Mdes Laboratones Afflgel 15 was purchased from BmRad. 
Polybrene and d o a c e t c  acid were from Aldnch  Protenrequenong reagents were products of 
Beckman, danrylGlu-Gly-Arg-CH2CI and D-Phe-Pro-Arg-CHZCl were from Calbtochem TosCly- 
ProArgNA for the  determmatron of amldolytw  sctwlty of thrombm was obtamed lrom 
Boehnnger-Mannhem;  GdnHCl was from Pierce Monoclonal anhbodles IESTI, 2,6 ,  and 7) were 
obtamed from Amencan  Dmgnoshca DAPA was ryn thesmd  followmg the  procedure of 
Nerhem etd (32) Wsth the exrrptlon of the buffers used 10 prepare fnbrm monomer-agarose 
and  the €LISA. all bufferr used in thm study  mntamed 0.1% l w l v l  polyethylene glycol IM, = 80001 
to ilrnlt protem adsorptmn to surfaces 
l!jx&oovridoxvlation d a-Thrombin Pyridoxal S-phosphate modification of thrombln 
was carrled out esrentially as described prevmuriy (26) 100 pl of 25 mM pyndoxal 5 -phosphate 
mmture was rncubated m the dark at rwm temperature. Alter three hours. 500 pi of sodlum 
was added 10 10 ml of 26 pM thrombon ~n 100 mM tr~eth.nol.m~ne-acetale at  pH 8 0 ThrL 
borohydride (100 mM1 was added  and thts mlxNre was incubated  overntght at 4OC Pyndoxyl S. 
phosphate was removed by gel flltratnon chromatography (Sephadex G-251 Hepann-protected 
rnodlfncatmn was carr~ed out m the  presence of a lenfold  molar excess of hepar," to a-thrombm 
Hepann was removed  by  passage  of  the reactmn mixture over 1 DEAE-Sephacel column 
equtllbrated m 50 mM Tn5-HCI, 250 mM NaCl at pH 7 4 
ha 4 1  
. .  
danryl-Glu.Gly-Arg-CH2C1, and antithrombm 111 reactmn rates Were determmed for V a i O Y I  
Fibrmogen clothng activity, amidolytic actlulty. 
lormr of  thrombm as described  prewouriy (30,311 The  buffer lor the heparin tltraflon Of 
antathrombm 111-thhrombm reachon rates. however. was 20 mM HEPES. I50 mM NaCl at pH 7  4 
~-Phe-Pro-Arg-CH2C1-yy-th~~mbin war prepared by irquential addition. a1 10-min 
Intervals. of 10 p~  ahquotr of 10 mM of the ~ C I I V C  sltedmxted reagent B-Phe-Pra-Arg-CH~cl (In 
1 mM HCI) to 8 4 UM  n- thrombin in 20 mM HEPE5, 300 mM NaCl 1 1  pH 6 5 The exlent Of 
modhcatlon was followed by the 1 0 s  of ammdolyt~c substrate hydrolyrlr actlvity and was 
termmated when no actrwty remained. Rerldual D-Phe-Pro-Arg-CH2CI in the m o d l f l e d - r  
thrombm was removed by dlalyrs versu~ the HEPES buffer I4 x 4L at 40c)  
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of added heparin. (AI Thrombm derivanvcr (at 5 or IO n M 1  were Incubated with antithrombm 
Fi& 2. Inhibition  of  thrombin  derivatives by mtithmmbin 111 in the abrvncl md presence 
Ill (500 nM) at 250C in 20 mM HEPES, 150 mM NaCI, 2 5 or 5 0 mg/mL BSA, and 0.1 mglmL 
rctwity a-Thmmbm ( 0 ), unpmtected modifleda-thrombin ( T ), hcpann-proterted modified- 
Poiybrene Portions were withdrawn at mteIvds  and assayed for remaming thrombin amidolytic 
a-thrombin ( A ) and yy-thrombm ( ). ( 8 )  Thrombin denvativ- (0 5 n M )  were incubated with 
antithrornbm Ul (5 nM) in the HEPES buffer tn the presence of vanow cmcentration.5 of  hepuin. 
Second order rate Constant (kz) for thmmbm inhibition were determined a-Thrombin ( 0  ), 
unprotected modrfwd-a.thrombm ( v I. heparin-protected modified-a-thrombin ( A  ) and 
vthrombm ( 8 ) 
Essential Lysyl Residues of a-Thrombin 18425 
